NCT03535740 2025-07-31
ALTA-2
Takeda
Phase 2 Completed
Clinical Trials
3 trialsNCT06785584 2025-01-21
Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study
Fujian Medical University Union Hospital
Phase 4 Not yet recruiting
NCT03410108 2024-05-08
Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)
Takeda
Phase 2 Completed